ACM Global Laboratories — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ACM Global Laboratories is a long-established, privately-held contract research organization (CRO) focused on the diagnostics and clinical trial services sector. With over 45 years of operation, it has built a global footprint supporting trials in more than 65 countries through core service pillars: Central Lab Services, Bioanalytical Services, and Toxicology Services (via its DRUGSCAN brand). The company provides critical, data-driven laboratory testing and sample management, positioning itself as a specialized partner for the pharmaceutical and biotechnology industries in their drug development efforts.

Diagnostics

Technology Platform

Integrated global laboratory services platform specializing in clinical trial testing, bioanalytical assay development, sample management/logistics, and toxicology.

Opportunities

Growth is driven by increasing clinical trial complexity, demand for specialized biomarker and bioanalytical data, and the globalization of trials.

Expansion in niche areas like cannabinoid testing and medication monitoring presents additional avenues for revenue.

Risk Factors

Key risks include intense competition from larger CROs, dependence on the cyclical biopharma R&D sector, and operational risks related to global sample logistics and regulatory compliance.

Client concentration in a competitive bidding environment is also a factor.

Competitive Landscape

ACM competes in the central laboratory services market against large, full-service CROs (e.g., LabCorp, IQVIA) and other specialized central labs. Its differentiation lies in its long-standing niche focus, claimed superior sample retention, and specialized service lines like rescue studies and the DRUGSCAN toxicology brand.

More companies in Diagnostics & Precision Medicine →More companies in United States →